ASLN has been the topic of a number of other research reports. Zacks Investment Research cut shares of ASLAN PHARMACEU/ADR from a buy rating to a hold rating in a research note on Friday, July 26th. HC Wainwright set a $9.00 target price on shares of ASLAN PHARMACEU/ADR and gave the company a buy rating in a research note on Wednesday, June 5th.
Shares of ASLAN PHARMACEU/ADR stock traded down $0.09 on Thursday, hitting $3.21. 9,358 shares of the company’s stock were exchanged, compared to its average volume of 6,934. The firm has a 50-day moving average of $3.32. The company has a market capitalization of $102.48 million, a PE ratio of -2.30 and a beta of 2.10. ASLAN PHARMACEU/ADR has a 1 year low of $2.51 and a 1 year high of $8.85.
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.
See Also: What is the Consumer Price Index (CPI)?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.